Contract drug-development organization Ricerca Biosciences LLC is offering a new service that compares drug candidates to a large reference set of pharmacologically active compounds.
The new service, called Foresight, helps predict in vivo effects from in vitro drug data and provides insight into additional compound activities, according to a statement from Concord Township, Ohio-based Ricerca.
The analysis can help researchers avoid adverse effects and determine new indications for safe or novel compounds, according to the statement.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
“Foresight provides a glimpse into the future of a compound and uses data from the past to suggest ways to increase the acuity of that vision,” Ricerca CEO Ian Lennox said.
The company is offering the service for an introductory price of $3,500 per compound.